Based on a study featured in the Alzheimer’s Disease Journal, a 14-day course of high CBD dose assists in restoring functions of two crucial proteins that reduce the build-up of various plaques in the human brain (the basis of Alzheimer’s condition) and boosts cognition in a rodent model of early-onset Alzheimer’s.
Early-onset Alzheimer’s is a hereditary version of the sickness, and symptoms start showing in individuals in their thirty’s or forty’s. About 10-15% of individuals suffer from this hereditary version.
Dr Baban Babak, an immunologist and associate research dean at the Augusta Georgia Dental College of Georgia, said in a press conference that CBD reduced protein IL-6 levels related to the high levels of inflammation in Alzheimer’s. This cannabis compound also increased cognition in mice models involved in the study.
Dr John Morgan, a neurologist and the Movement and Memory Disorder Programs’ director, said that at the moment, they have two types of drugs that treat Alzheimer’s. One type boosts the neurotransmitter acetylcholine levels, that’s also reduced in Alzheimer’s, and the other functions through NMDA receptors associated with neuron communication and is essential to memory. Morgan further said that they have nothing that combats the disorder’s pathophysiology.
The researchers concluded that cannabidiol seemed to normalise TREM2 and IL-33 levels by tenfold and sevenfold, respectively. The researchers said that when these proteins are running low, it indicates the presence of the sickness. This is CBD’s first time to be found to restore these levels.
The researchers further said that the remaining steps include ascertaining optimal doses, issuing CBD earlier during the infection process and going towards potential medical tests. They are also exploring delivery systems, such as using an inhaler that could assist in delivering CBD directly to an individual’s brain.
Other co-authors of this study include Dr David Hess, Kumar Vaibhav (MCG neuroscientist) and Krishnan Dhandapani.